High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: A dose-escalation study

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3258-3265

  Yule, S M ^a   Foreman, N K ^a   Mitchell, C ^a   Gouldon, N ^a   May, P ^a   McDowell, H P ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; EPENDYMOMA; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; MALE; NEUROECTODERM TUMOR; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; VOMITING;

EID: 0030883957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3258     Document Type: Article

References (42)

1. Duffner PK, Cohen MR, Meyers MH, et al: Survival of children with brain tumors. SEER program 1973-1980. Neurology 36:597-601, 1986
2. Dropcho EJ, Wisoff JH, Walker RW, et al: Supratentorial malignant gliomas in childhood. A review of fifty cases. Ann Neurol 22:355-364, 1987
3. Grisby PW, Thomas PRM, Schwartz HG, et al: Irradiation of primary thalamic and brain stem tumors in a pediatric population. A 33 year experience. Cancer 60:2901-2906, 1987
4. Halperin EC, Wehn SM, Scott JW, et al: Selection of a management strategy for pediatric brainstem tumors. Med Pediatr Oncol 17:117-126, 1989
5. Allen JC, Bloom J, Ertel I, et al: Brain tumors in children. Current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. Semin Oncol 13:110-22, 1986
6. Torres CF, Rebsaman S, Siber JH, et al: Surveillance scanning of children with medulloblastoma. N Engl J Med 330:892-895, 1994
7. Kalifa C, Hartmann O, Demeoeq F, et al: High dose busulphan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors. A phase II study. Bone Marrow Transplant 9:227-233, 1992
8. Heideman RL, Douglass EC, Krance RA, et al: High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external beam radiotherapy in newly diagnosed paediatric malignant gliomas. J Clin Oncol 11:1458-1465, 1993
9. Findlay JL, Goldman S, Wang MC, et al: Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 14:2495-2503, 1996
10. Allen JC, Helson L: High dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55:749-756, 1981
11. Allen JC, Helson L, Jereb B: Preradiation chemotherapy for newly diagnosed brain tumors. A modified phase II trial. Cancer 52:2001-2006, 1983
12. Friedman HS, Mahaley S Jr, Schold SC Jr, et al: Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurg 18:335-339, 1986
13. Duffner PK, Horowitz ME, Krischer JP, et al: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328:1725-1731, 1993
14. Abrahamsen TG, Lange BJ, Packer RJ, et al: A phase I and phase II trial of dose-intensified cyclophosphamide and GM-CSF in paediatric malignant brain tumors. J Pediatr Hematol Oncol 17:134-139, 1995
15. Lachance DH, Oette D, Schold SC Jr, et al: Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms. Med Pediatr Oncol 24:241-247, 1995
16. Moghrabi A, Fuchs H, Brown M, et al: Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Med Pediatr Oncol 25:190-196, 1995
17. Sladek NE: Metabolism of oxazaphosphorines. Pharmacol Therapeut 37:301-355, 1988
18. Yule SM, Boddy AV, Cole M, et al: Cyclophosphamide metabolism in children. Cancer Res 53:803-809, 1995
19. Ayash LJ, Wright JE, Tretyakov O, et al: Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response. J Clin Oncol 10:995-1000, 1992
20. Brugger W, Birken R, Bertz H, et al: High dose cyclophosphamide chemotherapy blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophit and platelet recovery after high dose VP16, ifosfamide and cisplatin. Br J Haematol 84:402-407, 1993
21. Lansky LL, List MA, Lansky SB, et al: Toward the development of play performance scale for children (PPSC). Cancer 56:1837-1840, 1985
22. D'Argenio DZ, Schumitzy A: Adapt II Users Guide. Biomedical Simulations Resource. Los Angeles, CA, University of Southern California, 1992
23. Kedar A, Maria BL, Graham-Pole J, et al: High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med Pediatr Oncol 23:428-436, 1994
24. White L, McCowage G, Kannourakis G, et al: Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: A phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 12:522-531, 1994
25. Friedman HS, Schold C, Maheley S, et al: Phase II treatment of medulloblastoma and pineoblastoma with melphalan: Clinical therapy based on experiemental models with human medulloblastoma. J Clin Oncol 7:904-911, 1989
26. Chan LL, Ater J, Jaffe N, et al: Fractionated high-dose cyclophosphamide for advanced pediatric solid tumors. J Pediatr Hematol Oncol 18:63-67, 1996
27. Frei E III, Teicher BA, Holden SA, et al: Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48:6417-6423, 1988
28. Smith RD, Keher JP: Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity. Cancer Res 51:542-548, 1991
29. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al: Cardioloxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 141:758-763, 1981
30. Kupari M, Volin L, Suokas A, et al: Cardiac involvement in bone marrow transplantation. Bone Marrow Transplant 5:91-98, 1990
31. Hertenstein B, Stefanic M, Schmeiser M, et al: Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant. J Clin Oncol 12:998-1004, 1994
32. Mahoney DH Jr, Strather D, Camilla B, et al: High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: A pilot Pediatric Oncology Group study. J Clin Oncol 14:382-388, 1996
33. Braveman AC, Antin JH, Plappert MT, et al: Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evalualion of new dosing regimens. J Clin Oncol 9:1215-1223, 1991
34. Bouffet E, Mottolese C, Jouvet A, et al: Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 33:91-95, 1997
35. Egorin MJ, Kaplan RS, Salcman M, et al: Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clin Pharmacol Therapeut 32:122-128, 1982
36. Hommes OR, Aerts F, Bahr U, et al: Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosppression. J Neurol Sci 85:297-303, 1983
37. Yule SM, Boddy AV, Price L, et al: Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Med Pediatr Oncol 25:234, 1995
38. Sandstrom M, Freijs A, Larsson R, et al: Lack of relationship between sytemic exposure for the component drugs of the flurouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 14:1581-1588, 1996
39. Yule SM, Boddy AV, Cole M, et al: Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13-19, 1996
40. Forrester LM, Henderson CJ, Glancey MJ, et al: Relative expression of cytochrome P450 isoenzymes in human liver and association wilh the metabolism of drugs and xenobiotics. Biochem J 281:359-368, 1992
41. Walls MJ, Sullivan AM, Jamieson E, et al: Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: A analysis of progenitor-cell quantity and quatity and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 15:535-546, 1997
42. Gilbertson RJ, Jaros E, Perry PJ, et al: Mitotic percentage index: A new prognostic factor for childhood medulloblastoma. Eur J Cancer 33:609-615, 1997